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Abstract
Introduction
Syndecan-1 (Sdc1; CD138) is a major transmembrane heparan sulfate proteoglycan
expressed on the extracellular, luminal surface of epithelial cells and syncytiotrophoblast,
thus comprising a major component of the glycocalyx of these cells. The “soluble” (shed)
form of Sdc1 has paracrine and autocrine functions and is normally produced in a regulated
fashion. We compared plasma soluble Sdc1 concentrations, in relation to placental Sdc1
expression, in uncomplicated (control) and preeclamptic pregnancies.
Methods
We evaluated soluble Sdc1 across uncomplicated pregnancy, and between preeclamptic,
gestational hypertensive and control patients at mid-pregnancy (20 weeks) and 3rd trimester
by ELISA. Placental expression level of Sdc1 was compared between groups in relation to
pre-delivery plasma soluble Sdc1. Participants were recruited from Magee-Womens
Hospital.
Results
In uncomplicated pregnancy, plasma soluble Sdc1 rose significantly in the 1st trimester,
and reached an approximate 50-fold increase at term compared to post pregnancy levels.
Soluble Sdc1 was lower at mid-pregnancy in women who later developed preeclampsia
(P<0.05), but not gestational hypertension, compared to controls, and remained lower at
late pregnancy in preeclampsia (P<0.01) compared to controls. Sdc1 was prominently
expressed on syncytiotrophoblast of microvilli. Syncytiotrophoblast Sdc1 immunostaining
intensities, and mRNA content in villous homogenates, were lower in preeclampsia vs.
controls (P<0.05). Soluble Sdc1 and Sdc1 immunostaining scores were inversely associ-
ated with systolic blood pressures, and positively correlated with infant birth weight
percentile.
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Conclusion
Soluble Sdc1 is significantly lower before the clinical onset of preeclampsia, with reduced
expression of Sdc1 in the delivered placenta, suggesting a role for glycocalyx disturbance
in preeclampsia pathophysiology.
Introduction
The syncytiotrophoblast is a specialized, multinucleate epithelium formed by the fusion of
cytotrophoblasts within the placental villi. With its continuous exchange surface interfacing
with maternal blood, the syncytiotrophoblast microvillous membrane has critical functions
including transport of nutrients to the fetus [1]. Deficient uterine spiral artery remodeling (fail-
ure of spiral arteries to transform to high-flow, low-resistance conduits), frequently seen with
preeclampsia or fetal growth restriction (FGR), is thought to result in reduced or intermittent
blood flow to the intervillous space leading to syncytiotrophoblast dysfunction and damage
[2].
The surface of eukaryotic cells has a hydrated matrix of specialized proteoglycans and glyco-
proteins, linked to the plasma membrane, known as the glycocalyx [3,4] The vascular endothe-
lial glycocalyx is a critical regulator of vascular function, and endothelial glycocalyx damage
has been implicated in reperfusion oxidative injury, inflammation, atherosclerosis and diabetes
[3,5–10]. The syncytiotrophoblast microvillous membrane surface also has a substantial glyco-
calyx [11–13] but its functions are poorly understood.
Syndecan-1 (Sdc1; CD138) is a major transmembrane heparan sulfate proteoglycan
expressed on the surface (glycocalyx) of epithelial cells, endothelial cells and plasma cells
[14,15]. Sdc1 regulates diverse cell behaviors including adhesion, proliferation, motility, intra-
cellular signaling, growth factor and macromolecular cell surface binding and cellular internali-
zation, angiogenesis, lipid metabolism, wound healing, regulation of leukocyte migration, and
endothelial responses to fluid shear stress [14,16–20]. Sdc1 is strongly expressed on villus STB
microvillous membrane, but not on cytotrophoblast or stroma, extravillous trophoblast, nor
fetal vascular endothelium [21–27]. Expression of Sdc1 on the STB microvillous membrane is
reportedly reduced in preeclampsia [21,22,25] and iatrogenic IUGR with fetal compromise
[26], compared to uncomplicated pregnancy.
Extracellular domains of Sdc1 are constitutively shed from the glycocalyx, typically in pro-
cesses regulated by sheddases (e.g., matrix metalloproteinases and heparanase)[3,28]. The solu-
ble form of Sdc1 is thought to have important functions as a paracrine and autocrine effector,
and competitor of transmembrane Sdc1 for growth factors and other extracellular ligands
[14,15,20]. Sdc1 shedding is an important response in wound healing with effects on inflamma-
tion, proliferation and remodeling [3,15,20]. Circulating soluble Sdc1 concentrations can be
increased by excess reactive oxygen species or inflammatory stimuli, as exemplified by the
extremely high values observed with sepsis [3,10,28,29].
Soluble Sdc1 concentrations have not been systematically examined in uncomplicated (nor-
mal) or preeclamptic pregnancies. Our initial hypothesis was that plasma soluble Sdc1 levels
would increase with advancing normal pregnancy, and increase significantly more so before
and after the onset of preeclampsia in association with reduction of Sdc1 immunoreactivity on
STB of villous placenta. The rationale was based on the concept that the increased systemic
inflammation thought to underlie the pathogenesis of preeclampsia, representing an accentua-
tion of the normal inflammatory response to pregnancy [30], might be a stimulus for increased
Sdc1 shedding. We first measured soluble Sdc1 longitudinally in maternal plasma from
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uncomplicated pregnancies, by trimester and proximally postpartum. We then investigated if
concentrations of soluble Sdc1 were different at 20 weeks’ gestation, before clinical onset of dis-
ease, and late pregnancy after disease onset, in women who later developed preeclampsia com-
pared to normotensive controls and women who later developed gestational hypertension
(without proteinuria). In a different set of preeclampsia cases and controls we compared villous
placental Sdc1 expression profile, and looked for correlations with clinical variables and plasma
Sdc1. Finally, to test for lasting constitutional differences, we measured plasma soluble Sdc1
one year after delivery, comparing non-pregnant women with a history of preeclampsia to
women with a history of uncomplicated pregnancy.
Methods
Comparison groups
We conducted a nested, case-control study of pregnant women enrolled between 1999 and
2012 as part of an ongoing longitudinal and cross-sectional investigation of preeclampsia
(Pregnancy Exposures and Preeclampsia Prevention Study; PEPP) at Magee-Womens Hospital
and Magee-Womens Research Institute, Pittsburgh, PA, USA. Written informed consent was
obtained from all study subjects. The University of Pittsburgh Institutional Review Board
approved the study. The study participants had also given permission to be contacted for addi-
tional preeclampsia-related research studies upon consenting to participate in the PEPP Proj-
ect. A subset women enrolled in PEPP were thus evaluated 1 year after pregnancy, with
separate University of Pittsburgh IRB approval and written informed consent.
We studied 5 different subsets of patients as follows. These groups were mostly non-over-
lapping, reflecting comparison criteria.
1. We evaluated gestational changes in soluble Sdc1 using longitudinal maternal plasma sam-
ples from 8 women with uncomplicated pregnancy, at gestational weeks 7–11, 17–26, 37–
41; and 24–48 hours postpartum and 4–9 weeks postpartum. Patient characteristics are
given in S1 Table.
2. Comparisons of plasma soluble Sdc1 at mid-pregnancy were performed. Nine women in
this study set developed preeclampsia later in the pregnancy, 9 developed gestational hyper-
tension (without proteinuria) later in the pregnancy, and 19 had an uncomplicated preg-
nancy outcome (characteristics summarized in Table 1). The samples were matched for
gestational age (mean gestational weeks ~20, range 18–24). Gestational age-matched 3rd tri-
mester samples were not sufficiently available from these patients.
3. We compared 17 women with preeclampsia to 17 with uncomplicated pregnancy, and 8
women with gestational hypertension to 8 women with uncomplicated pregnancy, during
the 3rd trimester after disease onset (described in S2 and S3 Tables). Fifteen of 17 women
with preeclampsia delivered pre-term whereas all of the women with gestational hyperten-
sion delivered at term. Therefore, women with preeclampsia were matched by gestational
age to controls who delivered at term but had provided earlier 3rd trimester samples at the
time of routine prenatal care visits. Women with gestational hypertension were matched by
gestational age to a different set of controls with samples obtained immediately before
delivery.
4. Both villous placental tissue and maternal plasma samples were obtained at the time of
delivery from 19 women with preeclampsia and 25 women with uncomplicated pregnancies
(samples not matched for gestational age at delivery). Clinical characteristics are given in
Table 2. Two preeclampsia cases and 2 controls were also in study set #3, above.
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5. We evaluated soluble Sdc1 levels in plasma from a separate set of 17 women with a history
of preeclampsia and 19 with history of uncomplicated pregnancy, 1 year after delivery
(S4 Table).
Patient criteria
Women were prospectively recruited in the outpatient clinics or inpatient setting and all deliv-
eries occurred at Magee-Womens Hospital. Patients with a history of chronic hypertension
(determined by subject history and/or antihypertensive medication use prior to the preg-
nancy), diabetes, chronic renal disease or other significant metabolic disorders, current infec-
tion, fetal malformations or chromosomal abnormalities, multifetal gestation, or a positive
toxicology screen were excluded. A panel of PEPP principal investigators and clinicians met
monthly to adjudicate pregnancy outcomes. Controls were normotensive and without protein-
uria throughout gestation, and delivered healthy babies in the absence of infection. Preeclamp-
sia was defined as gestational hypertension with proteinuria, in accordance with standard
criteria at the time (2000 National High Blood Pressure Education ProgramWorking Group
Report on High Blood Pressure in Pregnancy) [31]. Gestational hypertension was defined as
persistent, new onset hypertension (systolic 140 mm Hg and/or diastolic 90 mm Hg)
appearing after 20 weeks’ gestation and reverting post pregnancy. Threshold for proteinuria
was 300 mg of protein in a 24-hour urine collection, a dipstick of 2+ or greater, a catheterized
Table 1. Clinical characteristics of uncomplicated pregnancy control (n = 19), gestational hypertensive (n = 9), and preeclampsia (n = 9) groups;
for comparison of soluble Sdc1 in gestational age-matched, 2nd trimester maternal plasma.
Uncomplicated Pregnancy (n = 19) Gestational Hypertension (n = 9) Preeclampsia (n = 9)
Age (years) 24 (20–35) 22 (19–36) 24 (17–41)
BMI pre-pregnancy (kg/m2) 29 (23–36) 26 (22–37) 31 (23–45)
Gestational weeks at venipuncture 19.7 (17.7–23.9) 19.9 (17.7–24.4) 19.4 (18.4–22.3)
Gestational weeks at delivery 40 (29–42) 40 (38–41) 38 (30–40) a,c
Early gestational BP (<20wks.):
Systolic (mm Hg) 114 (99–126) 119 (111–137) 116 (109–130)
Diastolic (mm Hg) 69 (59–80) 73 (64–86) 70 (68–78)
Pre-delivery BP:
Systolic (mm Hg) 126 (104–138) 144 (141–163) b 148 (141–193) a
Diastolic (mm Hg) 73 (55–80) 90 (78–94) b 97 (89–114) a
Birth weight percentile 75 (30–91) 41 (16–60) b 23 (1–93) a
Uric acid (mg/dL) — 4.8 (3.7–5.4) 5.9 (5.1–8.7) c
Cigarette smokers (n, %) 0 (0%) 0 (0%) 0 (0%)
Race (n, % Black) 9 (47%) 4 (44%) 5 (56%)
Infant Sex (n, %Female) 10 (53%) 4 (44%) 3 (33%)
Preeclampsia with preterm delivery (n, %) 4 (44%)
Preeclampsia with SGA infants (n,%) 2 (22%)
Continuous variables are displayed as median (range); categorical variables are displayed as n (%). BMI, body mass index; BP, blood pressure. Early
gestational BP: mean of all gestational blood pressures obtained prior to 20 weeks’. Preeclampsia with preterm delivery: preeclampsia with delivery before
37 weeks of gestation. Preeclampsia with SGA infants: preeclampsia with small-for-gestational-age (SGA) defined as birthweight percentile less than 10th.
a Significant difference between preeclamptics and controls (P<0.05)
b Significant difference between gestational hypertensives and controls (P<0.05)
c Significant difference between preeclamptics and gestational hypertensives (P<0.05)
Group differences in continuous variables evaluated by Kruskal-Wallis with post hoc Dunn’s test; Categorical variables by Fisher’s Exact Test.
doi:10.1371/journal.pone.0157608.t001
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sample of 1+ or greater, or a protein to creatinine ratio 0.3. Our research-specific criteria for
preeclampsia also included gestational hyperuricemia (>1 standard deviation above normal val-
ues for gestational age) [32]. The inclusion of hyperuricemia is thought to reduce the number of
women misclassified as preeclamptic [32]. Women in the gestational hypertension outcome
group manifested hypertension after gestational week 20 but not proteinuria.
Gestational age at delivery was based on last menstrual period and ultrasound, the latter
available in most cases. Preterm birth was defined as delivery before 37 completed weeks of
pregnancy. Gestational age-specific birth weight percentiles, adjusted for sex and race, were
based upon data from Magee-Womens Hospital. Maternal race was by self-report at enroll-
ment. Because of the small percentage of women who identified their race as other than black
or white (<3%), results are reported as black or other. Pre-pregnancy body mass index [weight
(kg)/height (m)2] was based on measured height and maternal self-report of pre-pregnancy
weight at the initial clinic visit. Cigarette smoking status (any smoking since suspected preg-
nancy) was by self-report; these data were obtained at the time of sample collection; we previ-
ously demonstrated no significant discordance between self-report of smoking status and
maternal plasma cotinine concentrations [33].
Table 2. Clinical characteristics of uncomplicated pregnancy (n = 25) and preeclampsia (n = 19) groups for placental evaluations.
Uncomplicated Pregnancy (n = 25) Preeclampsia (n = 19) P-Value
Age 28 (20–38) 28 (17–36) 0.643
BMI pre-pregnancy (kg/m2) a 27 (20–50) 27 (21–36) 0.611
Gestational weeks at delivery 39 (24–42) 33 (28–40) <0.001
Early Gestational BP: b
Systolic 114 (58–127) 110 (98–127) 0.728
Diastolic 70 (61–110) 73 (57–77) 0.671
Pre-Delivery BP:
Systolic 121 (50–137) 156 (130–177) <0.001
Diastolic 72 (55–120) 95 (82–117) <0.001
Baby Weight (grams) 3005 (525–3889) 1825 (561–3400) 0.001
Birth weight percentile 56 (11–94) 20 (0–93) 0.018
Placenta Weight (grams) c 447 (214–380) 410 (130–660) 0.206
Uric Acid N/M 6.59 (4.7–12.5) -
Cigarette Smokers (n, %) 2 (8%) 1 (5%) 1.00
Race (n, % Black) 9 (36%) 6 (31%) 0.547
Infant Sex (n, % Female) 15 (60%) 10 (53%) 0.771
Antenatal steroids (n, %) d 2 (9%) 12 (67%) <0.001
Delivery by Cesarean section (n, %) 11 (44%) 7 (37%) 0.76
Cesarean with labor (n, %) 3 (27%) 5 (71%) 0.14
Labor (n, %) e 13 (52%) 16 (84%) 0.05
Preeclampsia with preterm delivery (n, %) 17 (89%)
Preeclampsia with SGA infants (n,%) 7 (37%)
Continuous variables displayed as median (range); categorical variables displayed as n (%). P-values comparing preeclamptics vs. controls (Continuous:
Mann-Whitney Test, Categorical: Fisher’s Exact Test); N/M: not measured.
a Data missing for 1 women with preeclampsia.
b Data missing for 1 woman with uncomplicated pregnancy and 5 women with preeclampsia.
c Data missing for 11 women with uncomplicated pregnancy and 4 women with preeclampsia.
d Data missing for 2 women with uncomplicated pregnancy and 1 woman with preeclampsia.
e Number (percentage) of patients with labor at the time of delivery.
doi:10.1371/journal.pone.0157608.t002
Low Soluble Syndecan-1 Precedes Preeclampsia
PLOS ONE | DOI:10.1371/journal.pone.0157608 June 14, 2016 5 / 18
Soluble syndecan-1
Blood samples were collected into sterile, ethylenediaminetetraacetic acid (EDTA)-containing
collection tubes. The tubes were centrifuged for 20 min at 2,000 x g at room temperature por-
tioned into aliquots and the plasma stored at −80°C without thaw until used. Concentrations
of soluble Sdc1 in maternal plasma were measured in duplicate by ELISA (Diaclone sCD138
solid phase sandwich ELISA, Cell Sciences Inc., Canton, MA.) according to manufacturer’s
instructions. The minimum detectable concentration was 4 ng/mL. The intra and inter-assay
coefficients of variation were 6 and 10%, respectively. We performed sample dilution tests on
separate pools of preeclampsia and uncomplicated pregnancy plasma; there was good linear
correlation between the degree of sample dilution and measured Sdc1 concentrations, using
1:4, 1:8, and 1:16 (vol/vol) dilutions of each pool within the dynamic range of the assay (r2 =
0.90).
Placental Immunohistochemical Staining and Scoring
We obtained placental biopsies immediately after elective Cesarean section or vaginal delivery
from regions free of infarcts, between the margin and cord insertion. The villous tissue was cut
into 0.5 cm3 pieces and rinsed with ice-cold phosphate buffered saline. After rinsing, portions
of villous tissue were flash frozen and then placed into embedding medium (optimal cutting
temperature compound, OCT, Tissue-Tek, Inc). Frozen OCT-embedded placentas were sec-
tioned (7-μm), fixed in acetone, and peroxidase quenched by 3% H2O2. Acetone-fixed sections
are appropriate for surface (CD) proteins [34]. Immunostaining was accomplished using the
VECTASTAIN Elite ABC Kit, with anti-Sdc1 ectodomain antibody (H-174 rabbit anti- human
polyclonal; sc-5632, Santa Cruz Biotechnology, Dallas TX) at 1:100 dilution, with blocking
serum and 3, 3-diaminobenzidine supplied by the kit. Tissues were counterstained with hema-
toxylin (Vector Laboratories, Burlingame, CA). Negative controls were prepared by replacing
the primary antibody with blocking serum. Bright field images were collected using a Nikon90i
microscope and CCD camera (QImaging, Surrey, BC, Canada). Visual scoring of the STB of
placental villi was performed on 4x magnification images, on a 0–4 semi-quantitative scale
with 4 being the darkest stain along the entire apical surface. Images were scored by 2 techni-
cians pre-trained to the scale but unaware of the source of the tissue. The weighted Cohen’s
kappa coefficient for the 0–4 scoring between the technicians was 0.64, indicating “substantial”
agreement. The values from each scorer were averaged.
Western Blot Comparisons of Syndecan-1 in Placental Homogenates
Details are provided under Supporting Information (S1 Method). Twenty to thirty milligrams
of frozen pulverized villous tissue was homogenized by sonication and further prepared for
Western blot. Human recombinant CD138 (Diaclone ELISA, Cell Sciences Inc., Canton, MA)
was used as a standard, and Precision Plus Protein Kaleidoscope Standards (Bio Rad Technolo-
gies, Hercules, CA) were used as molecular weight ladder. Blots were incubated with a rabbit
polyclonal antibody against human Sdc1 ectodomain (H-174; Santa Cruz Biotechnology), fol-
lowed by goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology). Protein bands were detected
by enhanced chemiluminescence. We used Amido Black as a loading control, as this total pro-
tein stain optimally reflects total protein concentration for semi-quantitative Western blot of
placental homogenates [35]. The developed films were scanned into TIFF files and densitome-
try was carried out using digitizing software, UN-SCANIT™ Gel Version 4.3 (Silk Scientific
Inc., Orem, UT).
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Isolation and Analysis of Placental RNA
Total cellular RNA was isolated from placental tissue with TRIzol reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer instructions. After isolation, double- and single-
stranded DNA was removed by treatment with DNase I (Invitrogen). Purity of RNA was deter-
mined by measuring absorption at 280 and 260 nm. The cDNA was synthesized from 2 μg of
RNA, converted to cDNA using an Applied Biosystems (Foster City, CA) high capacity cDNA
kit. Control reactions without reverse transcriptase were performed to confirm the absence of
DNA contamination. Quantitative real-time polymerase chain reaction (PCR) was performed
on a TaqMan ABI PRISM 7700 sequence detector using 96-well optical plates (Applied Biosys-
tems). Real-time PCR was performed using inventoried TaqMan Gene Expression Assays for
syndecan-1 (Hs00896423_m1), syndecan-2 (Hs00299807_m1), glypican-1 (Hs00157805_m1)
and 18s (Hs99999901_s1) (Applied Biosystems). The 18s gene expression assay was used as an
endogenous reference for all samples. All amplification cycles were performed in a 50μl reac-
tion in duplicate with cDNA equivalent to 100ng of total RNA. Relative quantification of the
target expression was performed using the comparative cycle threshold (CT) method as
described in Applied Biosystems User Bulletin #2, with normalization of the number of target
gene copies (e.g., Sdc1) to an endogenous reference (18s) and relative to a calibrator (an
uncomplicated pregnancy placenta).
Statistical Analyses
Continuous data are expressed as median (range). Categorical data are given as frequencies (n)
and percentages (%). Longitudinal changes in plasma soluble Sdc1 across normal pregnancy
were evaluated using Repeated Measures Analysis of Variance on Ranks with post hoc Student-
Newman-Keuls test. Non-parametric tests (Mann-Whitney U or Kruskal-Wallis with post hoc
Dunn’s test) or Students’ t-test were used as appropriate to compare continuous data between
groups. Between-group placental expression data were compared using ANCOVA on ranks,
both with and without adjustment for gestational age. Fisher’s Exact test was used for categorical
variables. Spearman’s rho correlations were computed to investigate bivariate relationships.
Results
Maternal plasma soluble Sdc1 concentrations across uncomplicated
pregnancy
Clinical characteristics are summarized in S1 Table. As shown in Fig 1, soluble Sdc1 concentra-
tions increased significantly with advancing gestation, with highest values observed just prior
to delivery [median ng/ml (range): 1415 (365–3000)], followed by a substantial decrease at 11–
17 hours postpartum. With one exception (blood sample obtained 2 days before labor) the pre-
delivery samples were obtained after labor onset. In additional samples between 27–29 weeks
(before labor) from 4 patients, soluble Sdc1 was nearly double the corresponding value at 17–
26 weeks (median mg/mL: 696 vs. 376), further indicative of progressive gestational increases.
Soluble Sdc1 at 7–11 weeks of pregnancy [median ng/ml (range): 218 (102–290)] was approxi-
mately 7 times higher when compared to 4–9 weeks postpartum [28 (13–114) ng/mL; P<0.05]
(Fig 1), the latter not different from values in the women with history of uncomplicated preg-
nancy assessed 1 year postpartum [27 (13–61) ng/mL; see postpartum data, below.].
Mid-pregnancy comparison of soluble Sdc1
We compared soluble Sdc1 in gestational age-matched, mid-pregnancy (range 18–24 weeks)
samples from 9 women who later developed preeclampsia, 9 who developed gestational
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hypertension (without proteinuria), and 19 with uncomplicated pregnancy. Clinical data are
given in Table 1; all were non-smokers. There were no between-group differences in gestational
age at the time of blood sampling, maternal age, body mass index, early gestational blood pres-
sures, or racial distribution. All of the gestational hypertensive and uncomplicated pregnancy
patients in this cohort delivered at term, with appropriate-for-gestational- age (AGA) infants.
As shown in Fig 2, soluble Sdc1 concentrations were significantly lower, weeks before clinical
development of preeclampsia [median ng/mL 174 (range 48–353)], but not gestational hyper-
tension [242 (111–1187)], compared to controls [272 (78–1463)] (P<0.05, Kruskal-Wallis,
post hoc Dunn’s). Examining the groups separately, we found no significant correlations of sol-
uble Sdc1 with the clinical variables listed in Table 1.
Mid-gestation plasma soluble Sdc1 levels (at median gestational weeks 19.2 vs. 20.1, P = 0.74)
were lower in women who later developed early-onset preeclampsia (gestational age at delivery
<37 weeks; n = 4) compared to late-onset preeclampsia (gestational age at delivery 37 weeks;
n = 5), but not significantly so [median ng/mL 163 (range 104–207) vs. 195 (158–251); P = 0.38].
The two preeclampsia patients who later delivered SGA infants had mid-gestation soluble Sdc1
values (161 and 217 ng/mL), straddling the overall preeclampsia group median (174 ng/mL).
Cross-sectional 3rd trimester study of soluble Sdc1
We compared 17 women with preeclampsia, with plasma obtained after disease onset, to 17
normotensive controls (S2 Table). The samples were obtained before any labor, and group ges-
tational ages at the time of blood sampling were equivalent. The age, pre-pregnancy body mass
index, early gestation blood pressures, percentage of cigarette smokers, and racial distribution
did not differ between groups. Circulating soluble Sdc1 was ~2.5-fold lower in women with
preeclampsia [median ng/mL (range): preeclampsia 281(101–2237) compared to controls 705
(243–2861); P<0.01]. The median birth weight percentile in the preeclampsia group was 11.3
(range 1–78). Eight of the 17 cases delivered babies that were small-for-gestational-age (SGA),
defined as birth weight percentile<10. Median centile of this sub-group was 3 (range 1–9).
Despite one high value outlier (2237 ng/mL), soluble Sdc1 levels in this SGA-preeclampsia
Fig 1. Soluble Sdc1 concentrations increased significantly with advancing gestation. Box-plot of
soluble Sdc1 concentrations in maternal plasma as a function of successive gestational weeks (W) and
postpartum stages, of n = 8 women with uncomplicated pregnancy outcome. The solid and dotted lines
through the interior of the boxes correspond to median and mean values, respectively. The top and bottom of
each box correspond to 75th and 25th percentiles, respectively. Horizontal lines on the top of the graph
indicate significant differences between the time points (P<0.05; Repeated Measures Analysis of Variance
on Ranks with post hoc Student-Newman-Keuls test).
doi:10.1371/journal.pone.0157608.g001
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sub-group were significantly lower than controls [median pg/mL (range): 225 (101–2237);
P< 0.01]; these SGA-preeclampsia values, at gestational age 31 (range 26–33) weeks, were
comparable to those observed at 7–11 weeks of uncomplicated pregnancy (Fig 1). In contrast,
median soluble Sdc1 values in the preeclampsia sub-group with AGA infants [584 (159–1529)]
only trended lower than controls (P = 0.18). The gestational age at time of blood sampling did
not differ between controls and SGA-preeclampsia or AGA-preeclampsia.
In contrast, among plasma samples matched for gestational age at term prior to delivery (S3
Table), soluble Sdc1 in women with gestational hypertension [median ng/mL (range): 923
(443–1358)] did not differ significantly from controls [1308 (475–1637); P = 0.12].
Soluble Sdc1 correlated with infant birth weight percentile in women with gestational hyper-
tension (r = 0.69, P<0.05) and their controls (r = 0.79, p<0.03), but the correlation was marginal
in preeclamptic women (r = 0.45, P = 0.07) and not significant in their controls (r = 0.05,
P = 0.84). No other correlations between soluble Sdc1 and clinical variables were found.
Placental Sdc1 expression and plasma soluble Sdc1 in preeclampsia
and controls
Preeclampsia and control placentas were evaluated; patient clinical characteristics are summa-
rized in Table 2. Sdc1 immunoreactivity was prominent on villous syncytiotrophoblast but not
Fig 2. Plasma soluble Sdc1 is reduced at 20 weeks gestation in women who later develop
preeclampsia. Box-plot of soluble Sdc1 concentrations in mid-pregnancy maternal plasma by pregnancy
outcome group. The solid line through the interior of each box and the accompanying numerical value
corresponds to the group median. The dotted line through the interior of each box denotes arithmetic mean.
The top and bottom of each box correspond to 75th and 25th percentiles, respectively. The whiskers (t bars)
on the bottom denote the 10th percentile, and those on the top the 90th percentile. Solid circles represent
outlier values. The horizontal line, on the top of the graph indicate significant difference between control and
preeclampsia groups (P<0.05; Kruskal-Wallis with Dunn’s Post-hoc test).
doi:10.1371/journal.pone.0157608.g002
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detected on fetal villous vasculature (Fig 3). There was no discernable between-group differ-
ence in localization of the protein. The Sdc1 intensity score for Sdc1 on syncytiotrophoblast
was significantly lower in preeclampsia (n = 19) [2.0 (1.0–3.5)] vs. controls (n = 25) [(3.0 (1.0–
Fig 3. Representative images of Sdc1 immunoreactivity in preeclampsia (A) compared to
uncomplicated pregnancy (B) villous tissue. Note the more intense staining on syncytiotrophoblast of
uncomplicated pregnancy (immunohistochemical score = 4) compared to preeclampsia (score = 1), and
apparent absence of staining in fetal villous vasculature throughout. Gestational age at delivery was 36.6
weeks for both placentas. C: Sample Western blot of villous tissue homogenates from the preeclampsia and
control patients; band densities at the expected 85 kDa are consistent with reduced Sdc1 protein mass in
preeclampsia. See also Table 3 for summary group data.
doi:10.1371/journal.pone.0157608.g003
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4.0)] (P<0.001, Unadjusted Rank ANCOVA). This difference remained significant (P<0.02)
after adjusting for gestational age (Table 3). Presence or absence of labor did not appear to
influence the Sdc1 immunostaining intensity score in either outcome group (data not shown),
although the distribution of preeclampsia placenta samples collected in the presence (n = 16)
vs. absence (n = 3) of labor was inadequate for meaningful assessment. Comparing the pre-
eclampsia and uncomplicated pregnancy placentas exposed to labor, the intensity score for
Sdc1 on syncytiotrophoblast was significantly lower in preeclampsia with labor (n = 16) [2.25
(2.0–3.0)] vs. controls with labor (n = 13) [(3.0 (2.5–4.0)] (P<0.03).
We compared Sdc1 protein expression in villous tissue homogenates by Western blot, using
all available samples from the same patients (n = 16 preeclampsia, 16 controls). By densitome-
try, median Sdc1 band intensities were lower in the preeclampsia group (P< 0.05; Table 3, Fig
3), consistent with the immunohistochemistry scores. However, differences were not signifi-
cant after adjustment for gestational age (P = 0.13). Sdc1 mRNA expression level in the villous
tissue homogenates was roughly half in preeclamptic women (n = 16) compared to controls
(n = 20), significant both with and without adjustment for gestational age (Table 3). Syndecan-
2 and glypican-1 mRNA did not differ by group.
Soluble Sdc1 was measured in pre-delivery maternal plasma, available from most of these
patients (n = 17 preeclampsia, n = 19 controls). Soluble Sdc1 was lower in preeclampsia
(P<0.02, Rank ANCOVA), but not after adjustment for gestational age (P = 0.20) (Table 3).
Sdc1 immunostaining score correlated with villous Sdc1 protein (by Western blot) in pre-
eclamptic women (r = 0.52, P<0.05). Plasma soluble Sdc1 levels correlated with both villous
Sdc1 protein (r = 0.54, P<0.03) and mRNA (r = 0.59, P<0.02) in controls. Pre-delivery systolic
blood pressure correlated inversely (negatively) with immunostaining score in preeclamptic
women (r = -0.50, P<0.05), with villous Sdc1 protein in controls (r = -0.75, P<0.001) and with
soluble Sdc1 levels in controls (r = -0.54, p<0.03). Although not significant within each group
separately, immunostaining score correlated significantly with birth weight percentile (r = 0.43,
P<0.01) among all patients combined. Pre-pregnancy BMI correlated inversely with villous
Sdc1 protein in both preeclamptic women (r = -0.54, P<0.04) and controls (r = -0.67, P<0.01).
Table 3. Placental and pre-delivery plasma data, corresponding to the uncomplicated pregnancy (n = 25) and preeclampsia (n = 19) groups
described in Supplementary S4 Table.
Outcomes Uncomplicated Pregnancy
(n = 25)
Preeclampsia
(n = 19)
Unadjusted Rank
ANCOVA
*Adjusted Rank
ANCOVA
Sdc1 immunoreactivity score a 3 (1–4) 2 (1–3.5) <0.001 <0.02
Sdc1 expression, normalized to total protein
(Amido Black)b
2.34 (1.41–4.37) 2.15 (1.23–2.73) <0.05 0.126
Sdc1 mRNA c, d 0.45 (0.08–8.47) 0.23 (0.11–1.57) <0.01 <0.01
Syndecan-2 mRNA c, d 0.6 (0.13–5.70) 0.21 (0.11–1.03) 0.06 0.09
Glypican-1 mRNA c, e 0.94 (0.25–16.14) 0.52 (0.19–2.00) 0.295 0.552
Soluble Sdc1 (ng/mL) f 1035 (171–3750) 495 (166–2236) <0.02 0.254
Variables are displayed as median (range)
*Adjusted for gestational age
a Immunoreactivity score: semi-quantitative ordinal (0 to 4+) scale by blinded observer, with absent staining considered scored as zero.
b Data missing for 9 women with uncomplicated pregnancy and 3 women with preeclampsia.
c Placental villous biopsy tissue mRNA content estimated by RT-PCR, comparative CT method, with units relative to a normal pregnancy placenta = 1.0.
d Data missing for 5 women with uncomplicated pregnancy and 3 women with preeclampsia.
e Data missing for 6 women with uncomplicated pregnancy and 3 women with preeclampsia.
f Data missing for 6 women with uncomplicated pregnancy and 2 women with preeclampsia.
doi:10.1371/journal.pone.0157608.t003
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Gestational age at delivery correlated significantly with circulating soluble Sdc1 (preeclampsia
r = 0.49, P<0.05; control: r = 0.64, P<0.01), and with villous mRNA in controls (r = 0.51,
P<0.03).
Soluble Sdc1 concentrations postpartum
Wemeasured plasma soluble Sdc1 one year after completed pregnancy, comparing 17 non-
pregnant women with a history of preeclampsia compared to 19 women with a history of
uncomplicated pregnancy. These women were studied after first pregnancy, with the exception
of two women with history of preeclampsia who were enrolled after their second completed
pregnancy (one with recurrent preeclampsia, and one with preeclampsia in second pregnancy
but unknown first pregnancy history). Study participants presented to the Magee-Womens
Hospital Clinical and Translational Research Center in the morning after an overnight fast. At
that time they completed a health history questionnaire, underwent a physical examination
(weight, height, blood pressure, heart rate) and a urine test to rule out pregnancy, and a fasting
blood sample was obtained. All women were non-lactating at the time, had no pre-pregnancy
or current history of renal or vascular disease, and were nonsmokers (S4 Table). Plasma soluble
Sdc1 concentrations were not different post-pregnancy [median ng/mL (range): women with a
history of preeclampsia 23 (5–72) vs. control 27 (13–61); P = 0.98]. Soluble Sdc1 did not signifi-
cantly differ post-pregnancy between women with a history of preterm vs. term preeclampsia,
or between women with a history of preeclampsia with SGA vs. AGA infants (data not shown).
We found no significant correlations of soluble Sdc1 with the clinical variables listed in S4
Table.
Discussion
The glycocalyx is a negatively charged, gel-like mesh on the apical surface of epithelial and
endothelial cells. The syncytiotrophoblast microvillous membrane surface has a substantial gly-
cocalyx, but neither its normal functions nor its status/role in pregnancy disorders have been
sufficiently evaluated. Both acute insults (e.g., ischemia/reperfusion, volume loading, heart sur-
gery) and chronic conditions (e.g., sepsis, atherosclerosis and diabetes mellitus) can lead to
damage to the vascular endothelial glycocalyx[36,37]. Shedding of the Sdc1 extracellular
domain, and of other glycocalyx constituents such as hyaluronic acid and heparan sulfate, is
normally regulated by matrix metalloproteinases and heparanases. However, shedding can be
accentuated by tumor necrosis factor-alpha, oxidized lipoproteins, reactive oxygen species, and
other inflammatory mediators [3,10,28,29].
Given evidence for a role of inflammation in the pathogenesis of preeclampsia we originally
hypothesized that soluble Sdc1 would be elevated in women with the syndrome. Contrary to
hypothesis, we found that soluble Sdc1 concentrations are significantly lower during the sec-
ond trimester, ~16 weeks before clinically apparent preeclampsia, and in the 3rd trimester after
disease onset but before any labor, compared to controls with uncomplicated pregnancy. This
pattern in gestational age-matched samples was not observed in women with gestational hyper-
tension compared to controls, suggesting that reduced soluble Sdc1 is not simply a biomarker
of hypertensive pregnancy. Although we cannot rule out the presence of subclinical disease at
the time of blood sampling, these data suggest that Sdc1 dysregulation is an early event in pre-
eclampsia pathogenesis.
Our study further shows that maternal plasma concentrations of soluble Sdc1 rise progres-
sively with advancing pregnancy. By 7–11 weeks of pregnancy, concentrations were approxi-
mately 7-fold higher than values at 4–9 weeks after delivery. Soluble Sdc1 levels at term
(median 1415 ng/mL) are similar to those reported during sepsis [10,38], and represent an
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approximate 50-fold increase over the postpartum levels. Concentrations normalized substan-
tially toward early pregnancy levels within 24–48 hours postpartum. Our data do not preclude
the possibility of labor and delivery (uterine contractions) causing a substantial increase in sol-
uble Sdc1; systematic evaluation of this would require serial samples/measurements during the
delivery. However, median soluble Sdc1 concentrations in the normotensive controls with 3rd
trimester samples obtained before any labor (S2 Table; median gestational week 32.0) were
roughly 25-fold higher than values in different controls measured at 4–9 weeks after delivery
(Fig 1) or 1 year after delivery.
A prior study reported that serum Sdc1 concentrations rise with normal pregnancy
(159-fold increase at term compared to nonpregnancy), with increases occurring mostly
between weeks 20 and 30 of pregnancy[39]. However, that study reported even higher serum
levels in patients with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome
compared to normotensive controls matched by gestational age. Only two preeclampsia
patients in our entire study manifested elevated liver enzymes and thrombocytopenia (hemoly-
sis data not available); soluble Sdc1 values in these patients were below the preeclampsia
median. The reason for the discrepancy between the two studies is not clear. However, 40% of
the HELLP patients in the cited study did not fulfill diagnostic criteria for preeclampsia, and
very few evidently had growth restricted/SGA infants as birth weights were on average 102
grams over that predicted on the basis of customized charts [39]. It is possible that HELLP syn-
drome as a distinct, severe disease involves widespread glycocalyx shedding with release of sol-
uble glycans.
Using an antibody that recognizes the Sdc1 ectodomain (H-174), we found substantial
expression of syndecan-1 on the STB of placental villi, but no detectable expression on fetal vil-
lous vasculature. This agrees with previous reports using several different monoclonal or poly-
clonal anti- Sdc1 antibodies, in which the apical surface of STB was extensively
immunoreactive for Sdc1, but not evident on cytotrophoblast, stroma, extravillous trophoblast,
or fetal vascular endothelium [21–27]. The rise in soluble Sdc1 with advancing pregnancy com-
bined with the rapid decline in soluble Sdc1 levels within hours after delivery, and the robust
expression of Sdc1 on STB in direct contact with maternal blood, suggest that the placenta is a
major source of the high levels of soluble Sdc1 in the maternal circulation during pregnancy.
Consistent with this hypothesis, we have observed that villous tissue fragments in explant cul-
ture produce appreciable amounts of soluble Sdc1 (~10 ng/mg tissue/24 hours) under 8%O2/
5%C02, 37°C incubation conditions (author’s unpublished data). However, this does not rule
out maternal vasculature or blood cells as a significant source of soluble Sdc1 during
pregnancy.
Our immunohistochemical, Western blot and mRNA data collectively indicate a decrease in
placental Sdc1 expression with preeclampsia. The lack of matching for gestational age in the
evaluation of preeclamptic and control placentas may be viewed as a limitation of our study.
Seventeen of 19 preeclamptic placentas but only 2 of 25 controls in our placental analyses deliv-
ered preterm (gestational age<37 weeks). Nevertheless, group differences in immunostaining
score and mRNA expression were significant after adjustment for gestational age. This agrees
with previous reports of reduced expression of Sdc1 on STB microvillous membrane [21,22,25]
or decreased Sdc1 in villous homogenates measured by ELISA [25], in which differences from
controls were independent of gestational age. There is one contrasting report of an overall
increase in expression of Sdc1 on STB, accompanied by significantly lower soluble Sdc1 con-
centrations in maternal serum, in preeclampsia (with or without HELLP syndrome) compared
to normal controls[40]. Using an antibody (MI15) recognizing an extracellular epitope of the
core protein, the authors reported focally reduced or absent Sdc1 immunoreactivity on the api-
cal microvillous surface despite an overall increase in cytoplasmic Sdc1 in preeclampsia. When
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complicated with HELLP syndrome, however, the STB apical surface showed strong Sdc1 posi-
tivity. The authors suggested that abnormal cytoplasmic accumulation/retention of Sdc1 below
the apical membrane occurs with preeclampsia, and that this might contribute to the observed
reduction of soluble Sdc1 in maternal plasma [40]. We similarly used an anti-Sdc1 antibody
directed against the extracellular domain but did not have the resolution to distinguish surface
from cytoplasmic immunoreactivity. Our Western blot data using villous homogenates show
less pronounced group differences in Sdc1 compared to our immunostaining (Table 3), possi-
bly consistent with cytoplasmic versus membrane differences.
Our mid-pregnancy data are consistent with a possible contribution of soluble Sdc1 to the
pathogenesis of preeclampsia. It has been hypothesized that both the reduction in circulating
placental growth factor (PlGF) and the elevation of the antiangiogenic protein soluble fms-like
tryosine kinase 1 [sFLT1; the soluble decoy receptor for PlGF and vascular endothelial growth
factor (VEGF)]—that arise before clinically evident preeclampsia—are manifestations of syn-
cytiotrophoblast cellular stress or syncytiotrophoblast dysfunction [41]. Although speculative
at this point, the lower soluble Sdc1 in women destined to develop preeclampsia, and evidence
of downregulation of syncytiotrophoblast Sdc1 in women with the syndrome, may be another
expression of this stress response. The soluble Sdc1 ectodomain is known to function as a para-
crine and autocrine effector or competitor, and may have relevant functions by influencing
angiogenesis, coagulation pathways, inflammation, or lipid metabolism [14,20,28]. The shed
Sdc1 ectodomain can compete with intact syndecan by sequestering heparan sulfate-binding
ligands in the pericellular environment [28]. Syndecan-1 shedding is an important host
response that facilitates the resolution of neutrophilic inflammation, potentially by aiding the
clearance of pro-inflammatory chemokines. Soluble syndecans can act as extracellular chaper-
ones; for example soluble VEGF-Sdc1 complexes can activate VEGF receptors on endothelial
cells [14]. An excess of sFLT1 is thought to contribute to the pathogenesis of preeclampsia
[42]. Membrane-bound heparan sulfate proteoglycans bind sFLT1 electrostatically, thereby
regulating sFLT1 bioavailability [43]. Transgenic heparanase overexpression in mice signifi-
cantly increases circulating sFLT1 [43]. Concentrations of plasma sFLT1 in non-pregnant
women increase to late pregnancy levels shortly after intravenous heparin injection, suggesting
that significant quantities of sFLT1 are normally bound to glycocalyx heparan sulfate proteo-
glycans [44]. However, the influence of membrane-bound or soluble Sdc1 on sFLT1 kinetics
and activity has yet to be explored.
Conclusions
Maternal plasma concentrations of shed (soluble) Sdc1 rise ~50-fold with gestation and revert
postpartum. On average, women who later develop preeclampsia have lower levels of soluble
Sdc1 in maternal plasma at 20 weeks’ gestation (before clinical disease onset) compared to
women with uncomplicated pregnancy or gestational hypertension. Differences between
women with preeclampsia compared to controls remain evident after disease onset, especially
in preeclampsia with SGA neonates. Mirroring the differences in maternal circulation, pre-
eclampsia is characterized by reduced expression Sdc1 on the syncytiotrophoblast of placental
villi. There was no difference in concentration of soluble Sdc1 post pregnancy between women
with prior preeclampsia and prior uncomplicated pregnancies. These data are collectively con-
sistent with the placenta as a major source of soluble Sdc1, likely shed into the circulation at
reduced quantity in women who develop preeclampsia. The study datasets were small and
should be validated with larger cohorts. Because of the observational nature of our study we
cannot establish a causal relationship between maternal plasma Sdc1 levels and the subsequent
development of preeclampsia. Further studies are needed to determine the effects of altered
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Sdc1 kinetics on pregnancy physiology and its significance for placental and vascular glycoca-
lyx integrity and function in normal pregnancies and those complicated by preeclampsia.
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